We found that reduced B7-H3 inhibition upregulates MHC-II expression in Tsc2-deficient tumor cells in vivo, where high IFN-γ producing T cells are present in the tumor milieu (Fig. 6c, f, h, i). This evidence concerns the gene CD276 and neoplasm.